• 1
    Cosio FG, Dillon JJ, Falkenhain ME et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47: 11361141.
  • 2
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 3
    Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 15601565.
  • 4
    Gourishankar S, Hunsicker LG, Jhangri GS, Cockfield SM, Halloran PF. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14: 23872394.
  • 5
    Isoniemi HM, Krogerus L, Von Willebrand E, Taskinen E, Ahonen J, Hayry P. Histopathological findings in well-functioning, long term renal allografts. Kidney Int 1992; 41: 155160.
  • 6
    Nickerson P, Jeffery J, Gough J et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9: 482487.
  • 7
    Cosio FG, Grande JP, Larson TS et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 11301136.
  • 8
    Hariharan S, Johnson CP, Breshnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.
  • 9
    Isoniemi H, Taskinen E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 11951198.
  • 10
    Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients. Transplantation 1995; 59: 511514.
  • 11
    Nicholson ML, McCulloch TA, Harper SJ et al. Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 10821085.
  • 12
    Seron D, Moreso F, Bover J et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 151: 310316.
  • 13
    Kuypers DRJ, Chapman JR, O'Connell PJ, Allen RDM, Nankivell BJ. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 12221230.
  • 14
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 15
    Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 16621668.
  • 16
    Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002; 39: 762768.
  • 17
    Kasiske BL, Hem-Duthoy KL, Tortorice KL, Rao KV. The variable nature of chronic declines in renal allograft function. Transplantation 1991; 51: 330334.
  • 18
    Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 10171023.
  • 19
    Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646652.
  • 20
    Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 11591171.
  • 21
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 22
    Nickeleit V, Hirsch HH, Binet IF et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999; 10: 10801089.
  • 23
    Buehrig CK, Lager DJ, Stegall MD et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64: 665673.
  • 24
    Rush D. Protocol biopsies should be part of the routine management of kidney transplant recipients. Proc Am J Kidney Dis 2002; 40: 671673.
  • 25
    Salomon DR. Protocol biopsies should be part of the routine management of kidney transplant recipients. Conf Am J Kidney Dis 2002; 40: 674677.
  • 26
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434441.
  • 27
    Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 21292134.
  • 28
    Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 10461052.
  • 29
    Su X, Zenios SA, Chakkera H, Milford EL, Chertow GM. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004; 4: 15011508.
  • 30
    Seron D, Carrera M, Grino JM et al. Relationship between donor renal interstitial surface and post-transplant function. Nephrol Dial Transplant 1993; 8: 539543.
  • 31
    Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699705.
  • 32
    Isnard, Bagnis C, Tezenas Du et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002; 13: 29622968.
  • 33
    Niaudet P, Fuchshuber A, Gagnadoux MF, Habib R, Broyer M. Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1997; 58: S85S90.
  • 34
    Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 9981003.
  • 35
    Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953961.
  • 36
    Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 17761785.
  • 37
    Cosio FG, Henry ML, Pesavento TE, Ferguson RM, Kim S, Lemeshow S. The relationship between donor age and cadaveric renal allograft survival is modified by the recipient's blood pressure. Am J Transplant 2003; 3: 340347.
  • 38
    Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998; 66: 17361740.
  • 39
    Tracy RE, Strong JP, Newman WP, Malcom GT, Oalmann MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. Kidney Int 1996; 49: 564570.
  • 40
    Moreso F, Lopez M, Vallejos A et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 8288.
  • 41
    Nankivell BJ, Fenton-Lee CA, Kuypers DR et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515523.
  • 42
    Cosio FG, Pelletier RP, Sedmak DD et al. Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications. Transplantation 1999; 67: 690696.
  • 43
    Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 24092418.
  • 44
    Grimm P, McKenna R, Nickerson P et al. Clinical Rejection is Distinguished from Subclinical Rejection by Increased Infiltration by a Population of Activated Macrophages. J Am Soc Nephrol 1999; 10: 15821589.
  • 45
    Seron D, Moreso F, Ramon JM et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 18491855.